EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pulmonary arterial hypertension induces a metabolic and inflammatory hepatopathy

Madelyn J Blake, Sally E Prins, Jeffrey Blake, Lynn M Hartweck, Jenna B Mendelson, Steeve Provencher, Sandra Breuils-Bonnet, Sebastien Bonnet, Kurt W Prins

Journal of Clinical Investigation · 01.07.2026 · 136 (13)

DOI: 10.1172/jci201862 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 28.05.2026. Verfasst von Madelyn J Blake und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gazes Cardiac Research Institute, Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, U…. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Liver Diseases, Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Right ventricular failure (RVF) is a major determinant of mortality in pulmonary arterial hypertension (PAH), and hepatic dysfunction predicts adverse outcomes. However, the cell-specific effects of PAH/RVF on the human liver remain poorly defined. METHODS We performed single-nucleus RNA-seq (snRNA-seq) of autopsy-derived liver tissue from 5 patients with PAH and 4 healthy individuals (non-PAH) treated as controls and compared these findings with publicly available snRNA-seq datasets from nonalcoholic steatohepatitis (NASH) and Fontan-associated liver disease (FALD). Transcriptomic analyses were integrated with histologic assessment, mitochondrion-enriched proteomics, and correlations with clinical markers of PAH/RVF severity. RESULTS PAH livers showed cell-specific metabolic, inflammatory, and fibrotic remodeling distinct from NASH and FALD. PAH hepatocytes exhibited a hypoxia-adapted, Warburg-like metabolic phenotype with reduced fatty acid metabolism, gluconeogenesis, cytochrome P450 activity, and ketone metabolism. PAH endothelial cells demonstrated increased glycolytic pathway activity and altered adhesion/barrier signaling. PAH hepatic stellate cells (HSCs) displayed HIF-1 and PI3K/Akt pathway activation, increased IL-6 expression, and histologic evidence of perivascular fibrotic remodeling. PAH macrophages showed complement activation with reduced JAK/STAT signaling. HSC HIF-1 activity correlated with clinical markers of PAH/RVF severity. CONCLUSION PAH induces a distinct metabolic and inflammatory hepatopathy characterized by hepatocyte metabolic reprogramming, HSC activation, macrophage complement signaling, and suppressed ketone metabolism. These findings support PAH-associated hepatopathy as a disease-specific end-organ phenotype linked to RVF severity. FUNDING NIH grants F31 HL170585, R01 HL158795, and R01 HL162927.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionLiver DiseasesLiverHumansFemaleMaleAdultHepatic Stellate CellsMiddle AgedInflammationHepatocytesNon-alcoholic Fatty Liver Disease

Stichwörter der Autor:innen

CardiologyCardiovascular diseaseInflammationMetabolism

Autor:innen und Institutionen

  • Gazes Cardiac Research Institute, Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Cardiovascular Division, Lillehei Heart Institute, and.
  • Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, Minnesota, USA.
  • PAH Research Group, Institut Universitaire de Cardiologie et Pneumologie de Québec Research Center, Department of Medicine, Université Laval, Quebec City, Quebec, Canada.
  • Institute for Lung Health, German Center for Lung Research, Cardio-Pulmonary Institute, Justus-Liebig University Giessen, Giessen, Germany.

Förderung

  • NHLBI NIH HHS
  • NIH

Zitieren

APA

Blake, M. J., Prins, S. E., Blake, J., Hartweck, L. M., Mendelson, J. B., Provencher, S., Breuils-Bonnet, S., Bonnet, S., & Prins, K. W. (2026). Pulmonary arterial hypertension induces a metabolic and inflammatory hepatopathy. Journal of Clinical Investigation, 136(13). https://doi.org/10.1172/jci201862

Vancouver

Blake MJ, Prins SE, Blake J, Hartweck LM, Mendelson JB, Provencher S, et al. Pulmonary arterial hypertension induces a metabolic and inflammatory hepatopathy. Journal of Clinical Investigation. 2026;136(13). doi:10.1172/jci201862

BibTeX
@article{Blake2026,
  author = {Blake, Madelyn J and Prins, Sally E and Blake, Jeffrey and Hartweck, Lynn M and Mendelson, Jenna B and Provencher, Steeve and Breuils-Bonnet, Sandra and Bonnet, Sebastien and Prins, Kurt W},
  title = {Pulmonary arterial hypertension induces a metabolic and inflammatory hepatopathy},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {13},
  doi = {10.1172/jci201862}
}
Kostenlos starten →